Impact of sacubitril/valsartan on cardiac and systemic hypoxia in chronic heart failure
Summary: In heart failure patients with reduced ejection fraction, Sacubitril/valsartan (S/V) increased proBNP T71 glycosylation, which is regulated negatively by hypoxia via miR-30a in vitro. Using a cohort of 73 HFrEF patients who were transitioned from standard HF medication to S/V, we found that...
Main Authors: | Hélène Nougué, François Picard, Alain Cohen-Solal, Damien Logeart, Jean-Marie Launay, Nicolas Vodovar |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-01-01
|
Series: | iScience |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S258900422302597X |
Similar Items
-
The emerging role of sacubitril/valsartan in pulmonary hypertension with heart failure
by: Yu Xu, et al.
Published: (2023-05-01) -
Progress and prospects of Sacubitril/Valsartan: Based on heart failure with preserved ejection fraction
by: Ruoyu Jia, et al.
Published: (2022-11-01) -
Sacubitril/Valsartan for heart failure
by: Wenqin Dai, MM, et al.
Published: (2022-06-01) -
The Diuretic Effect of Sacubitril/Valsartan Might Be Clinically Relevant
by: Luís Beck-da-Silva, et al. -
Early experience of Sacubitril–Valsartan in heart failure with reduced ejection fraction in real‐world clinical setting
by: Charlotte Nordberg Backelin, et al.
Published: (2020-06-01)